Previous 10 | Next 10 |
Gainers: Inari Medical (NARI) +6%. Rhythm Pharmaceuticals (RYTM) +5%. Adaptive Biotechnologies (ADPT) +5%. The RealReal (REAL) +5%. Esperion Therapeutics (ESPR) +4%. Losers: GoodRx Holdings (GDRX) -6%. AlloVir (ALVR) -5%. Caribou Biosciences (CRBU) -5%. Arrowhead Pharmaceuticals (AR...
AlloVir (NASDAQ:ALVR) on Tuesday announced preliminary, blinded data from its ongoing phase 2 study of its T cell therapy posoleucel for the treatment of BK viremia in adults who have got kidney transplant. BK viremia is a common infection encountered after kidney transplantation. It can put ...
Phase 2 study completed enrollment ahead of schedule Posoleucel well-tolerated with no cases of graft rejection observed to date Overall decline in median BK viral load among patients completing 12 weeks of dosing with posoleucel or placebo (2:1 randomization) ...
Gainers: Apyx Medical (APYX) +39%. Enochian Biosciences (ENOB) +17%. Concert Pharmaceuticals (CNCE) +14%. GeoVax Labs (GOVX) +14%. Liquidia (LQDA) +13%. Losers: NRx Pharmaceuticals (NRXP) -57%. Avadel Pharmaceuticals (AVDL) -44%. Nurix Therape...
Gainers: REGENXBIO (RGNX) +8%. Passage Bio (PASG) +6%. Yellow Corporation (YELL) +6%. Fluence Energy (FLNC) +6%. Fate Therapeutics (FATE) +4%. Losers: Cytokinetics (CYTK) -5%. Golden Entertainment GDEN -5%. AlloVir (ALVR) -5%. Arcimoto (FUV) -4%. Canaan (CAN) -...
AlloVir press release (NASDAQ:ALVR): Q1 GAAP EPS of -$0.69 beats by $0.11. Cash, cash equivalents, and marketable securities of $201.4M. For FY2022, the company continues to expect operating expenses to be in the range of $130M to $145M, excluding non-cash stock compensation expenses. For f...
Initiated posoleucel registrational study to prevent six devastating viral infections and now enrolling high-risk allo-HCT patients in the U.S., Western Europe and Asia FDA granted RMAT designation to posoleucel for Phase 3 multi-virus prevention indication with an estimated a...
Gainers: RCM Technologies (RCMT) +25%. Meta Platforms (FB) +20%. Upwork (UPWK) +13%. Patterson-UTI Energy (PTEN) +13%. Noodles & Company (NDLS) +11%. Losers: Align Technology (ALGN) -20%. AlloVir (ALVR) -8%. O'Reilly Automotive (ORLY)-7%. Amge...
Gainers: Avadel Pharmaceuticals (AVDL) +31%. AlloVir (ALVR) +7%. Redbox Entertainment (RDBX) +6%. CymaBay Therapeutics (CBAY) +5%. Harpoon Therapeutics. (HARP) +5%. Losers: Protagonist Therapeutics (PTGX) -41%. Nkarta (NKTX) -6%. Provention Bio (PRVB...
Gainers: Inozyme Pharma (INZY) +15%. Clarus Therapeutics (CRXT) +10%. MedAvail (MDVL) +5%. Syros Pharmaceuticals (SYRS) +5%. Magenta Therapeutics (MGTA) +4%. Losers: AlloVir (ALVR) -10%. Rite Aid (RAD) -9%. Windtree Therapeutics (WINT) -7...
News, Short Squeeze, Breakout and More Instantly...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...